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ABSTRACT 
The ability to generate a robust immune response is integral to organismal homeostasis. Cells 
of the innate immune system are considered the first responders of immunity, and are 
therefore responsible for sensing both pathogens and endogenous danger signals and 
initiating a protective inflammatory response. To appropriately sense pathogens and danger 
signals, cells have developed intricate mechanisms for transducing signals from the 
extracellular environment into the cell. The integration of these signals is complex, resulting 
from crosstalk between many signaling pathways, but is critical to generating a coordinated 
biological response. In additional to the specialized mechanisms of innate immune cells to 
respond to antigens, these cells (like most) have evolved a complex set of adaptive 
mechanisms that maintain homeostasis during cell stress. Activation of innate immunity via 
pathogen invasion or the presence of danger signals can be considered an especially intense 
form of cell stress, thereby implicating these homeostatic pathways as components of the 
innate immune response.  
The work presented in this thesis relates to the molecular mechanisms by which cells of the 
innate immune system integrate signals from the microenvironment to produce a coordinated 
biological response. The aim was to elucidate the mechanisms by which innate macrophages 
transduce extracellular signals to activate important effector pathways, and to describe 
crosstalk between cell signaling pathways that mediate adaptive responses to cell stress. 
Finally, we looked to extend our understanding to pathophysiological settings, and 
investigated the mechanisms by which pathogens that cause cell stress generate an aberrant 
inflammatory response. In doing so, we described novel components of these signaling 
pathways, which may be exploited in designing novel therapeutics. 
In paper I, Gαi2 was identified as a critical signaling molecule in macrophage phenotype 
determination, functioning to transduce signals from the microenvironment to fine tune 
macrophage propensity towards an M1 inflammatory or M2 anti-inflammatory phenotype. In 
paper II, the immune receptor CD38 was shown activate the master transcriptional 
regulation of the autophagic/lysosome machinery, TFEB. We further identified the large 
kinase LRRK2 as essential in signal transduction downstream of CD38. In paper III, we 
described adaptive crosstalk between TFEB, an essential component of the cell stress 
response, and the typically proliferative WNT signaling pathway. Finally, in paper IV we 
describe how the SARS-Coronavirus open reading frame-3a causes multimodal necrotic 
death by activating multiple cell stress and innate immune pathways, resulting in aberrant 
inflammation. 
In summary, the work presented in this thesis extends our current understanding of the 
molecular mechanisms mediating the integration of signals in innate immune cells. We have 
identified several novel signaling mechanisms, which could lay the foundation for the 
development of targeted therapeutics. 
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1 INTRODUCTION 
Mammalian species are constantly interacting with microbes, forming relationships that can 
be symbiotic or pathogenic [1]. The immune system, which is a complex network of cells, 
tissues, and molecules that functions to prevent and eradicate infections, has evolved to cope 
with both symbiotic and pathogenic microbes. The immune system can broadly be divided 
into two arms; innate immunity mediates initial protection against invading pathogens, while 
adaptive immunity develops more slowly and mounts a more effective defense against 
infections. Innate immunity is characterized by hallmark pattern recognition receptors (PRRs) 
that recognize pathogen-associated molecular patterns (PAMPs) and danger-associated 
molecular patterns (DAMPs). Recognition of exogenous pathogenic or endogenous danger 
signals results in immediate activation of innate immune cells, initiating an inflammatory 
cascade that allows priming of innate immune effector cells and instructs the adaptive arm of 
immunity to generate pathogen specific protection [2]. Adaptive immunity, which develops 
over the course of days to weeks, entails the clonal expansion of cells that have undergone 
molecular rearrangement of DNA to express receptors specific for the invading pathogen. 
These cells then provide enhanced protection from the pathogen, and facilitate the production 
of long-lived cells with memory of the offending pathogen allowing rapid generation of an 
immune response if subsequently exposed [3]. 
The work presented in this thesis focuses primarily on cells of the innate immune system and 
elucidates some of the molecules and cell signaling pathways that are essential in integrating 
environmental signals into a coordinated biological response. Integration of these signals is 
complex and often requires crosstalk between multiple signaling pathways. This investigation 
is focused at the molecular level, revealing signal transduction mechanisms governing 
macrophage polarization, the upregulation of autophagy, cellular adaptation following cell 
stress, and pathogenic inflammation after severe acute respiratory syndrome (SARS) 
coronavirus (CoV) infection. Investigation of the molecular mechanisms underlying a process 
provides the advantage that it characterizes novel targets for the potential development of 
therapeutics. 
 
1.1 THE IMMUNE SYSTEM 
The immune system consists of a complex collection of cells, tissues, and molecules that 
mediates resistance to and clearance of infections. The immune system is broken down into 
the innate and adaptive arms, which mediate the initial non-specific response and the delayed 
specific response respectively [4]. Innate immunity consists first of physical barriers, such as 
the skin and mucosa, that function to keep invading pathogens (e.g. bacteria, viruses, and 
fungi) from entering the body. If pathogens breach this barrier, they are met by sentinel cells 
of the innate immune system that recognize antigens on pathogens and initiate the appropriate 
response. These cells include macrophages, dendritic cells (DCs), and neutrophils, whose key 
role is to identify pathogens via their PRRs and secrete cytokines and chemokines that 
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function to activate and recruit effector cells [5]. The initial secretion of chemokines and 
cytokines is an essential step in the amplification of the immune response, and macrophages 
play a key role in orchestrating the immune response via these processes. Macrophages and 
neutrophils additionally contribute to the innate immune response by directly engulfing and 
degrading pathogens via phagocytosis, an important mechanism for the eradication of 
pathogens [6]. DCs, on the other hand, are professional antigen presenting cells (APCs) that 
capture pathogens and present their antigens to lymphocytes (B-cells and T-cells) of adaptive 
immunity. While macrophages are also considered professional APCs, it is the DCs that 
typically migrate to the draining lymph node following antigen recognition and capture, 
where they facilitate generation of the adaptive response [7]. In this way, DCs act as a key 
bridge between innate and adaptive immunity. The adaptive response is generated over a 
period of days to weeks, as antigens presented by DCs results in the selection and activation 
of lymphocytes capable of recognizing antigens from the invading pathogen. Clonal 
expansion of the selected lymphocytes results in an improved ability to eradicate the invading 
pathogen. Finally, memory lymphocytes are generated during the adaptive immune response. 
These are typically senescent cells that lie dormant after eradication of the pathogen during 
primary challenge, but are rapidly activated upon exposure of the organism to the same 
pathogen, providing immunity [3]. 
A functional immune system is critical to human health and disease, which is underscored by 
the myriad of diseases resulting from both impaired or enhanced immune responses [8]. 
Immunodeficiencies can be classified based on the type of cell they affect, including 
phagocytes of innate immunity, T-cells of adaptive immunity mediating cellular immunity, or 
B-cells of adaptive immunity mediating humoral immunity. Primary immunodeficiencies of 
phagocytes, such as chronic granulomatous disease, presents symptomatically as recurrent 
bacterial infections and is associated with increased risk for life threating infections from 
common bacteria [9]. Children with severe combined immunodeficiency, which results in 
defects in both T-cell mediated cellular immunity and B-cell mediated humoral immunity, 
rarely live past the age of two if untreated [10]. While defects in immunity result in the 
obvious increased risk of life threating infections, aberrant inflammation similarly has 
negative effects on health and disease. The classical example of pathogenic aberrant 
inflammation is the clinical syndrome referred to as a cytokine storm. Dengue fever, Ebola 
virus, and several CoVs can result in an uncontrolled inflammatory response characterized by 
elevated cytokine levels; this results in increased vascular permeability, hemorrhage, organ 
failure, and can lead to death [11]. Immune reconstitution inflammatory syndrome (IRIS) 
subsequent to HIV infection is another example; the hallmark of IRIS is the paradoxical 
worsening of infection related symptoms following recovery of immune function due to 
treatment of HIV [12]. IRIS is believed to be mediated by hyperactivation of immune 
pathways [13]. 
One important feature of the immune system is the ability to differentiate between self and 
non-self, which in the context of the immune response to foreign pathogens is critical to 
avoid autoimmune disease [14]. However, the immune system has also been implicated in the 
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pathogenesis of non-infectious diseases [15]. For example, chronic exposure to sterile 
irritants such as asbestos or silica can lead to fibrosis of the lungs due to aberrant alveolar 
macrophage activation [16]. In atherosclerosis, macrophage mediated inflammation upon 
recognition of cholesterol crystals propagates disease pathogenesis [17]. In Alzheimer’s 
disease, microglia produce pro-inflammatory cytokines in response to the hallmark amyloid 
plaques, promoting neurotoxicity [18]. The immune system has also been implicated in the 
development of tumors. In physiological setting, the immune system identifies and destroys 
cancerous and pre-cancerous cells [19], while in the pathophysiological setting the tumor 
microenvironment is immunosuppressive and contributes to tumor development [20]. The 
mechanisms of immune involvement in sterile inflammation are not as well understood as 
pathogen driven inflammation, but the ability of the innate immune system to recognizes 
endogenous DAMPs is believed to be important. 
 Innate Immunity 
The innate immune system is an evolutionary conserved arm of host defense and is widely 
considered the first line against infection. While innate immunity includes physical barriers 
that prevent pathogen entry into the host, it also plays a critical role in initiating and 
propagating the inflammatory response following breaches of these barriers by pathogens. 
One defining feature of innate immunity is the use of non-specific PRRs that are germline 
encoded, which is in stark opposition to the highly specific receptors of adaptive immunity 
generated by lymphocyte clonal expansion from an infinitely diverse pool of receptors 
generated by gene rearrangement [2]. PRRs recognize conserved microbial patterns called 
PAMPs and endogenous danger signals called DAMPs. 
Innate immune cells have distinct classes of PRRs, which are from different families based on 
protein homology and localize to different subcellular structures. The Toll-like receptors 
(TLRs) and C-type lectin receptors (CLRs) are membrane bound; they are therefore found 
either on the cell surface associated with the plasma membrane or in endosomal 
compartments. Innate immune cells also have several cytosolic PRRs, including those of the 
NOD-like receptor (NLR) family, the RIG1-like receptor (RLR) family, and AIM2-like 
receptor (ALR) family [21, 22]. Of these, TLR signaling is the most well characterized and 
results in the activation of the critical inflammatory transcription factors, NF-κB, interferon-
regulatory factors (IRFs), and AP-1. Protein expression downstream of these transcription 
factors is essential for orchestrating the inflammatory response and the subsequent 
eradication of microbes. All hematopoietic cells of the innate immune system express PRRs, 
and the functions of the major innate immune cell types are discussed herein.  
1.1.1.1 Phagocytes: Neutrophils and Monocyte/Macrophages 
Neutrophils and cells of the monocyte-macrophage lineage are typically the first responders 
to pathogenic insults, as they are quickly recruited to sites of infection where they both 
initiate the inflammatory response by recognizing pathogens and ingest microbes for 
intracellular killing [4]. Neutrophils are the most abundant leukocytes in the blood, and 
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production of neutrophils from the bone marrow results in a rapid rise in neutrophil levels 
during acute infection [23]. Neutrophils are particularly effective at trans-endothelial 
migration, and are classically considered to be short lived, as they die shortly after 
extravasation into tissues. Recent advances have extended the role of neutrophils, suggesting 
they play a role in chronic inflammation and instructing adaptive immunity, but these 
potential functions of neutrophils are less well defined and require continued study [24]. 
Monocytes/macrophages are less abundant than neutrophils but are more critical in 
orchestrating the immune response as they survive in tissues for long periods of time. 
Typically, monocytes in the blood are recruited to extravascular sites of infection, where they 
differentiate into macrophages [4]. Macrophages are particularly important in the immune 
response, as they not only mediate the initial propagation of inflammation, but are also 
involved in the suppression of inflammation following pathogen eradication in order to 
facilitate a return to homeostasis [25]. It is now appreciated that several macrophages subsets 
exist, and that macrophages have heterogeneous and flexible phenotypes allowing both pro- 
and anti-inflammatory roles. Classically activated macrophages (termed M1 macrophages) 
are pro-inflammatory and typically produce high levels of inflammatory cytokines, including 
IL-1β, IL-6, IL-12, and TNF-α. Macrophages can be polarized towards an M1 phenotype in 
vitro by stimulation with the bacterial wall component lipopolysaccharide (LPS) [26]. 
Alternatively activated (M2) macrophages are anti-inflammatory in nature and promote tissue 
repair. M2 macrophages produce high levels of anti-inflammatory cytokines, including IL-10 
and TGF-β, and are polarized towards the M2 phenotype by IL-4 and IL-13 [27]. Both M1 
and M2 polarized macrophages are essential to the propagation of inflammation and the 
physiological resolution of inflammation respectively, though the mechanisms and 
environmental signals biasing macrophage phenotype are still poorly understood. 
1.1.1.2 Dendritic cells (DCs) 
DCs are stellate shaped cells that function at the interface of innate and adaptive immunity 
[28]. They process antigens after capture and present them to T-cells to facilitate the adaptive 
response. They also produce cytokines and chemokines that recruit and activate lymphocytes 
of adaptive immunity. DCs have two major avenues for antigen presentation; they typically 
present cytoplasmic antigens to CD8+ cytotoxic T-cells via the MHC Class I complex, and 
extracellular antigens to CD4+ helper T-cells via MHC Class II [4]. The MHC Class I 
complex is present ubiquitously on cells throughout the body, while antigen presentation via 
MHC II is hallmark of professional APCs [29]. DCs have the unique capacity for cross-
presentation, which is the ability to present extracellular antigens to cytotoxic CD8+ T-cells 
via MHC Class I [30]. This process is highly dependent on the cellular process of autophagy, 
which is a ubiquitous cell-autonomous homeostatic pathway [31]. DCs are a major 
mechanism of cross-talk between innate and adaptive immunity and are required for an 
integrated immune response. 
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1.1.1.3 NK Cells 
Natural Killer (NK) cells are important lymphocytes in the response to intracellular (viral) 
infections and cancer. Many intracellular viruses and tumors have evolved mechanisms to 
evade immune recognition, including the downregulation of the typically expressed MHC 
Class I molecule. NK cells provide a backup mechanism to eradicate pathogens/tumors 
employing MHC I downregulation to evade immune detection, as they recognize and kill 
cells that fail to expression MHC Class I [32]. They kill infected cells by a variety of 
mechanisms, including induction of the programmed cell death pathway apoptosis, direct cell 
lysis via granzymes and perforin, and via production of interferon (IFN)-γ which upregulates 
the antiviral response and macrophage killing [32].   
 Inflammation 
Inflammation is the primary physiological response to immunologic stimuli and is 
characterized by the delivery of leukocytes and plasma proteins to the site of pathogenic 
insult. Symptomatically, inflammation is described by heat, pain, redness, and swelling, and 
can vary in severity from a mild adaptive process to an aberrant severe life-threatening 
symptomology. Inflammation was initially described as a response to pathogenic invasion 
(PAMPs), but it is now appreciated that a myriad of stimuli including irritants and persistent 
endogenous danger signals (DAMPs) also initiate the inflammatory process [2]. Pathogenic 
insults typically occur in tissues, while most immune response proteins and cells are present 
in the blood. During inflammation, inflammatory exudate consisting of innate immune cells 
and blood proteins are delivered to the extravascular site of infection (or injury) via 
postcapillary venules [33]. Inflammation is critical in maintaining organism homeostasis as it 
promotes both pathogen eradication and wound/tissue repair, but excess inflammation is 
pathological and can result in autoinflammatory disease [33]. 
Propagation of the inflammatory response results from a well-orchestrated cascade that 
enhances the initial signal. The cytokines interleukin-1 beta (IL-1β) and tumor-necrosis factor 
alpha (TNF-α) are critical early pro-inflammatory cytokines that play central roles in 
initiating systemic inflammation [34]. The IL-1 protein family consists of eleven members, 
including IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra), and IL-18, all of which have been 
well studied. Cells of innate immunity, including blood monocytes, tissue macrophages, and 
DCs, are the primary produces of IL-1β in humans. It is synthesized as an inactive precursor 
(pro-IL-1β), which is a substrate for caspase-1 mediated cleavage upon inflammasome 
activation. After production of cleaved IL-1β via caspase-1 cleavage, IL-1β undergoes 
noncanonical secretion to promulgate the inflammatory response in both an autocrine and 
paracrine manner. [35]. Cellular responses to IL-1β are mediated by the IL-1 receptor (IL-
1R), which has a variety of systemic effects in the context of inflammation. IL-1β increases 
the mesenchymal expression of intracellular adhesion molecule 1 (ICAM-1) and endothelial 
expression of vascular adhesion molecule 1 (VCAM-1), allowing more efficient delivery of 
immunocompetent cells and immune proteins from the blood to the extravascular site of 
pathogenic insult [4]. IL-1β also increases the levels of blood neutrophils and several 
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important immunomodulatory proteins, including acute phase proteins and several cytokines 
(including IL-6) [36-38]. While IL-1β is important in eradication of infection following 
physiological inflammation, excess IL-1β can cause pathophysiological inflammation. 
Increased blood IL-1β levels presents clinically as fever, lowered pain threshold, 
vasodilation, and hypotension via IL-1R dependent increases in nitric oxide and 
prostaglandin E2. [39, 40]. Due to the pleiotropic effects and clinical manifestations of excess 
IL-1β, IL-1β neutralization has now become a mainstay treatment for autoinflammatory 
diseases.  
In addition to delivering cells and proteins to the extravascular tissue or immediate protection 
against pathogens, inflammation also instructs adaptive immunity to generate a robust, long 
term response. This is mediated primarily by DCs, which migrate to the draining lymph node 
upon antigen capture to present antigens to lymphocytes to activate the adaptive response.  
  Adaptive Immunity 
Adaptive immunity is mediated by B- and T-cells that express pathogen specific receptors 
and mediate long lasting immunity [3]. As cells of adaptive immunity are not the focus of this 
thesis, adaptive immunity will only be broadly described for completeness. During 
development, both B-cells and T-cells undergo somatic recombination of the genes encoding 
their receptors, the B-cell receptor (BCR) and T-cell receptor (TCR) respectively. Somatic 
recombination during development results in an infinitely diverse set of receptors, which are 
screened for reactivity against self via a complex set of mechanisms [41]. Only cells 
expressing functional receptors that do not bind self-antigens with high affinity are allowed to 
persist, minimizing the risk of B and T cell autoimmunity. Upon pathogenic invasion, DCs 
capture antigens and migrate to the germinal centers of lymph nodes, where they present 
antigens to B- and T-cells. Lymphocytes with receptors capable of recognizing the antigen 
are activated, where they expand (clonal selection) and eventually mediate immunity against 
the pathogen eliciting the response. 
1.1.3.1 T-cells 
T-cells are broken down into two major subsets,  CD4+ helper and CD8+ cytotoxic T-cells 
[42]. CD4+ T-cells recognize antigens presented on MHC Class II molecules, while CD8+ T-
cells recognize antigens presented on MHC Class I. T-cell differentiation occurs in the 
thymus, and CD4+/CD8+ lineage determination occurs in part through mechanisms related to 
the ability of a precursor T-cell’s TCR to bind MHC Class I or MHC Class II. Upon CD4+ 
helper T-cell activation, they proliferate and result in the secretion of various cytokines. They 
help activate effector CD8+ cytotoxic T-cells, which can directly kill infected cells via 
induction of apoptosis or direct cell lysis by granzymes and perforin [43]. CD4+ T-cells can 
also help activate B-cells, which produce antibodies upon activation. The specific 
mechanisms through which CD4+ helper T-cells differentially activate CD8+ effector T-cells 
and B-cells are complex and out of the scope of this thesis [44]. 
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1.1.3.2 B-cells 
Naïve B-cells express one of two classes of membrane bound antibodies, IgD or IgM. They 
are able to recognize antigens through this receptor (which is termed the BCR), and antigen 
binding initiates signaling through the BCR resulting in the activation and maturation of the 
naïve B-cell into an antibody secreting plasma cell that mediates humoral immunity [45]. 
Antibody responses to antigens can be T-cell independent or T-cell dependent, depending on 
whether CD4+ helper T-cell co-stimulation is required for response to the antigen. Upon 
prolonged stimulation with an antigen, B-cells produce antibodies with different heavy chain 
classes due to isotype switching, with specific isotypes having specialized functions to 
combat specific types of microbes. Antibodies directed against an antigen on the surface of a 
microbe can bind the microbe in the circulation, which has several functional consequences 
mediating immunity. Antibody binding can neutralize the ability of the microbe to infect host 
cells, blocking the infection from taking hold. Antibody binding can also coat microbes, a 
process termed opsonization. This provides a signal promoting their phagocytosis by 
neutrophils and macrophages. Antibody binding can also promote killing by NK cells, a 
process termed antibody dependent cellular cytotoxicity (ADCC). Finally, antibody binding 
can promote initiation of the complement cascade, which further opsonizes microbes for 
phagocytosis and provides a positive feedback signal for the development of humoral 
immunity [46]. 
 
1.2 RECEPTORS AND SIGNALING PATHWAYS MEDIATING INNATE 
IMMUNITY 
The work in this thesis focuses on the several signaling pathways that play important roles in 
macrophage biology and innate immunity, including signaling via TLRs (specifically TLR4), 
inflammasomes, G-protein coupled receptors, the calcium generating ectoenzyme CD38, and 
the WNT signaling pathway. These pathways all play an essential role in transducing signals 
from the extracellular environment into the cell and activate downstream pathways which 
functionally modulate the cell response. While most of these signaling pathways are 
conserved across cell types, cell specific variations exist for some of these pathways. Here, I 
present a brief introduction on each pathway, and discuss the known mechanisms through 
which these pathways signal with an emphasis on its role in macrophage biology. 
 Toll-like Receptors (TLRs) 
1.2.1.1 TLR  
The TLR family consists of 10 members in humans (TLR1-10) and 12 in mice (TLR1-9, 
TLR11-13). They are typically expressed on cells of the innate immune system, though they 
can also be found on cells of adaptive immunity. TLRs are membrane bound PRRs expressed 
either on the cell surface associated with the plasma membrane or in endocytic compartments 
[47, 48]. TLR4, which is the physiological receptor for LPS, is the most well studied TLR 
and localizes to the plasma membrane. Structurally, it is a type I transmembrane protein with 
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extracellular N-terminal LRR domain involved in PAMP/DAMP sensing and an intracellular 
Toll/IL-1 receptor (TIR) domain important for initiating signaling. Upon ligand engagement, 
TLR4 dimerizes with the two extracellular LRR domains sandwiching the ligand, while the 
intracellular TIR domain activates downstream signaling via homotypic interactions [47]. 
Several adaptor proteins exist that are critical in transducing signals downstream of TLR4, 
the most important of which are myeloid differentiation factor 88 (MyD88) and TIR domain-
containing adaptor-inducing interferon-β (TRIF). Myd88- and TRIF- dependent signaling 
thus constitute the two major arms of the response downstream of TLR4 [49].  
1.2.1.2 Myd88-dependent signaling and TRIF-dependent signaling 
Engagement of TLR4 by LPS results in rapid recruitment of MyD88, which plays a 
scaffolding role in the formation of a large complex required for activation of downstream 
effectors. Both IRAK1 and IRAK4 are recruited to the complex and activated, allowing the 
binding of the RING-domain containing E3 ubiquitin ligase TRAF6 and subsequent 
activation of the kinase TAK1. TAK1 then directly activates the MyD88 downstream 
effectors, the NFκB pathway and MAPK signaling [50]. NFκB is a transcription factor 
responsible for the upregulation of many pro-inflammatory cytokines including TNF-α and 
IL-6, both of which are secreted from macrophages following LPS stimulation [51]. NFκB in 
macrophages is also essential in the upregulation of pro-IL-1β, which is not secreted unless a 
separate signal results in activation of the inflammasome [52, 53]. Initiation of the MAPK 
signaling cascade results in activation of the downstream transcription factors ERK1/2, 
JNK1/2, and p38 [54], which provide crosstalk aiding the upregulation of proinflammatory 
cytokines. While the MyD88-dependent rapidly activates transcription of pro-inflammatory 
cytokines, TRIF-dependent signaling is essential for the upregulation of type 1 IFN genes 
[55]. TRIF-dependent signaling results in the downstream activation of the kinases TBK1 and 
IKKi, which together phosphorylate and activate IRF3. IRF3 transcriptionally upregulates 
several type I IFN genes that are important in the response to LPS. 
 Inflammasomes 
Inflammasomes are critical mediators of the early inflammatory response, as they generate 
IL-1β upon activation [56]. Inflammasomes consist of three key components: a sensor 
molecule, the adaptor protein ASC, and caspase-1. ASC contains two notable conserved 
structural domains; it has an N-terminal caspase activation and recruitment domain (CARD) 
and a C-terminal pyrin (PYD) domain [57]. Inflammasomes are typically named for their 
sensor molecule, which is a cytosolic PRR capable of recognizing specific PAMPs or 
DAMPs. The most well studied inflammasomes include the NLRP3, AIM2, and NLRC4 
inflammasomes which recognize cellular stress, cytosolic DNA, and bacterial flagellin 
respectively. Activation of the sensor molecule results in its oligomerization and the 
subsequent recruitment of ASC, which forms a large protein speck due to homotypic PYD-
PYD mediated multimerization. Caspase-1 is then recruited to the ASC speck via its CARD 
domain, promoting its autocatalytic activation. Active caspase-1 cleaves pro-IL-1β and pro-
IL-18, generating their biologically active counterparts [58].  
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Importantly, inflammasome activation is a two-step process. It first requires a priming signal 
(signal 1) which in vitro is typically provided by LPS. This signal activates NFκB and 
promotes the transcriptional upregulation of IL-1β. For the NLRP3 inflammasome, priming 
additionally induces the transcriptional upregulation of NLRP3 and licenses NLRP3 
assembly by deubiquitination of NLRP3 [53]. Next, a sensor specific stimulus (signal two) is 
required for activation of the sensor molecule. In this way, inflammasome activation is tightly 
regulated, as aberrant inflammasome activity has serious pathologic consequences [59-61]. 
 G-protein Signaling 
1.2.3.1 G-protein coupled receptors (GCPRs) 
G-protein coupled receptors are a large family of evolutionarily conserved proteins involved 
in transducing stimuli from the microenvironment into intracellular signals [62]. They 
mediate the majority of cellular responses to external stimuli, including light, odors, 
hormones, growth factors, and many immune signaling molecules [63]. GPCRs are of 
considerable interest to human health and disease, as the human genome encodes over 800 
GPCRs and almost 35% of all FDA approved drugs target GPCRs. Nonetheless, 56% of non-
olfactory GPCRs remain unexplored in clinical trials. Many of these unexplored GPCRs are 
known to have effects on the immune system, therefore GPCRs present an area with 
untapped therapeutic potential for immune-related diseases [64]. GPCRs transduce signals 
upon ligand binding by coupling to heterotrimeric G-proteins, which in their resting state 
consist of a GDP-bound Gα subunit in complex with a Gβγ heterodimer. GPCR activation 
induces GTP nucleotide exchange on Gα, causing its dissociation from the Gβγ heterodimer. 
Upon dissociation, both GTP-bound Gα and Gβγ heterodimers transduce signals via their 
corresponding downstream effector molecules. Signaling continues until the inherent GTPase 
activity of Gα subunits results in the hydrolysis of GTP to GDP, allowing re-association of 
GDP-bound Gα and Gβγ to terminate signaling. This cycle plays a critical role in cell 
signaling networks, allowing environmental signals to be transduced and integrated into a 
coordinated intracellular biological response [65].  
1.2.3.2 Gαi and associated regulatory proteins 
The functional versatility of GPCR signaling is mediated in part by the existence of several 
subtypes of G proteins. G-proteins are functionally defined by their Gα subunit, of which four 
families exist: Gαs, Gαi/ Gαo, Gαq/Gα11, and Gα12/13 [66]. The Gαi subunit is of particular 
importance in the immune system, as it is highly expressed across a variety of leukocytes 
[67]. Classically, the GTP-Gαi reduces intracellular cyclic-AMP levels by inhibiting certain 
adenylate cyclase isoforms [68]. In murine macrophages, which express the Gαi2 and Gαi3 
isoforms, this is not believed to be a major mechanism of Gαi mediated signaling due to the 
lack of Gαi sensitive adenylate cyclase isoforms in these cells.  
In addition to the traditional GPCR-G-protein-effector template, there are several G-protein 
regulatory proteins that exert their biological function by modulating G-protein signaling. 
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These regulatory proteins are typically classified into two groups, regulators of G-protein 
signaling (RGS) and activators of G-protein signaling (AGS) [69]. The RGS family contains 
more than 30 proteins and is defined by the presence of an RGS domain, which mediates 
their interaction with Gα subunits [67]. RGS proteins are negative regulators of G protein 
signaling, as they act as GTPase accelerating proteins (GAPs) thereby limiting the duration of 
Gα signaling [67, 70]. They enhance the intrinsic GTPase activity of Gα by stabilizing the 
GTPase transition state, which can accelerate the intrinsic Gα GTPase activity by 100-fold 
[71]. Accordingly, G-proteins modified to be insensitive to RGS function show higher basal 
levels of signaling [67]. As their name suggests, the AGS proteins function to activate G-
proteins independent of receptor coupling [72]. AGS3 and AGS4, which enhance Gβγ 
signaling by directly binding GDP-bound Gα, are of particular interest due to their relatively 
high expression levels in macrophages [73, 74].  
1.2.3.3 Role of Gαi in macrophages 
The role of Gαi signaling in macrophages remains unclear, due to a variety of experimental 
approaches that have functionally implicated Gαi in macrophage biology without illuminating 
the molecular details. Studies on several Gαi-coupled GPCRs in macrophages, including 
formyl-peptide receptor 2, the chemokine receptor CXCR3, and Chemeren receptor 23 have 
implicated these GPCRs in macrophage polarization, as multiple cognate ligands drive either 
M1 or M2 polarization in ligand specific manner [75-79]. However, experimental approaches 
studying Gαi-coupled GPCRs are limiting in that it remains unclear which effects are due to 
Gαi signaling, Gβγ signaling, or non-canonical G-protein signaling. Other studies have 
implicated Gαi in signal transduction downstream of TLR4, but many of these studies relied 
on inhibition of Gαi by pertussis toxin (PTX) [80-82]. While treatment with PTX to inhibit 
Gαi is useful in many settings, it remains unclear if the effects of PTX truly phenocopy the 
loss of Gαi. A few studies have used genetic deletion of Gαi in murine bone marrow derived 
macrophages (BMDMs) and show defects in phagocytosis and chemotaxis following loss of 
Gαi [83]. However, more studies are needed to fully understand the role of Gαi in macrophage 
biology. 
 CD38 and Calcium Signaling 
CD38 is a member of the evolutionarily conserved ADP-ribosyl cyclase family of proteins, 
which are named for their ability to generated cyclic-ADP-ribose (cADPR) from 
nicotinamide adenine dinucleotide (NAD). The defining member of this family is the Aplysia 
ADP-ribosyl cyclase [84], and in addition to CD38, the human genome encodes for another 
family member named BST1 [85]. CD38 exists as a 46 kDa glycosylated type II membrane 
protein with a long extracellular C-terminal domain and a short 21 aa cytoplasmic tail [86]. 
CD38 is highly expressed in lymphoid and myeloid cells of the immune system, and has 
multiple enzymatic functions enabling the production of calcium mobilizing second 
messengers [87]. In addition to the earlier described ADP-ribosyl cyclase activity used to 
generate cADPR from NAD, CD38 can generate the second messenger ADP-ribose (ADPR) 
from NAD via its glycohydrolase activity [88, 89]. In acidic compartments, such as 
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endosomes and lysosomes, CD38 can utilize NADP to generate NAADP through a base 
exchange reaction [90, 91].  
Notably, all second messengers generated by CD38 mobilize calcium from different sources. 
The major intracellular calcium stores include the endoplasmic reticulum and lysosomes, 
while calcium entry from the extracellular space can be mediated by receptors on the plasma 
membrane. ADPR binds TRPM2 on the plasma membrane to mobilize extracellular calcium 
[92], cADPR mobilizes ER calcium via Ryanodine Receptors (RyRs) [93], while NAADP 
targets two pore channels (TPCs) on the lysosome [94, 95]. Significant cross-talk has been 
shown to exist between these calcium stores. For example, NAADP directly targets the 
lysosomal two pore channels (TPCs), mobilizing lysosomal calcium. This then promotes 
amplification of the calcium signal by mobilizing calcium from other stores, a process termed 
calcium induced calcium release (CICR) [94, 96, 97]. In addition to initiating calcium 
signaling through production of second messengers, ligation of CD38 with antibodies can 
initiate distinct signaling pathways that do not require CD38 enzymatic activity. These 
pathways have been described in B-cells and have been shown to influence proliferation or 
death of several B cell subsets [98, 99]. 
Despite involvement in intracellular signaling pathways, the physiological function of CD38 
remains unclear. In macrophages, CD38 is strongly upregulated after exposure to immune 
stimuli and has been suggested as a marker for M1 murine macrophage polarization [100, 
101]. Studies have also implicated CD38 in promoting inflammation downstream of LPS and 
suggest CD38 plays a role in enabling phagocytosis by inducing calcium release after 
phagosome formation [102, 103]. Finally, CD38 has been implicated in autophagy. CD38 
deficient cells have autophagic activation defects following stimulation with LPS [104], 
while in vivo studies in mouse models of coronary atherosclerosis similarly show autophagic 
defects in CD38 deficient mice [105, 106]. Finally, CD38 is very highly expressed in B cell 
tumors, especially in multiple myeloma. The monoclonal anti-CD38 antibody Daratumumab 
is already FDA approved for multiple myeloma, while the monoclonal Isatuximab is in phase 
III clinical trials [86, 107]. In addition to antibody-dependent cell-mediated cytotoxicty, these 
antibodies induce direct cytotoxicity via activation of intracellular pathways [108, 109]. 
Despite clinical use of these monoclonal antibodies (mAbs), the molecular mechanisms 
mediating signaling downstream of CD38 remain unclear.  
 WNT/β-catenin signaling 
The final signaling pathway covered in this thesis is the Wingless/integrated (WNT) signaling 
pathway. WNT signaling has been primarily studied in the context of development and 
cancer, but recent advances show roles for WNT signaling in immune cells [110-112]. WNT 
signaling is a complex pathway activated by Wnts, which are the physiologic ligands of 
Frizzled (FZD) receptors. The most well studied WNT pathway is the WNT/β-catenin 
pathway, which results in downstream activation of T cell factor/lymphoid-enhancer binding 
factor (TCF/LEF) proteins (TCFs) [113]. In the WNT OFF state, TCFs bind Transducin-
Like-Enhancer of split proteins (TLEs), where they act as transcriptional repressors on WNT 
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response elements. Upon activation of WNT signaling, TLEs in complex with TCFs are 
replaced by the transcriptional co-activator β-catenin, and TCF/β-catenin complexes promote 
transcription of WNT target genes [114-116].  
β-catenin stabilization is the key step in Wnt/β-catenin signaling. In the absence of signaling, 
free β-catenin is quickly degraded by the Wnt destruction complex, which consists of the 
scaffold protein Axin1, the kinases CK1α/δ and GSK3α/β, the tumor suppressor protein 
APC, and β-catenin [117]. The kinases in this complex, CK1 and GSK3, mediate the 
constitutive phosphorylation of β-catenin inducing its ubiquitination by the E3 ligase β-TrCP 
and subsequent degradation [118-120]. Upon activation of WNT signaling, the destruction 
complex is localized to the cell membrane and inhibited, thereby allowing β-catenin levels to 
rise rapidly and accumulate both in the cytoplasm and nucleus [121]. Nuclear β-catenin then 
displaces TLEs to associate with TCFs, resulting in the transcriptional activation of Wnt 
target genes [115]. 
The WNT/β-catenin pathway is anabolic in nature, and has been implicated in several 
important processes including cell proliferation, cell migration, and cell fate determination 
[122]. The processes controlled by Wnt signaling are bioenergetic, requiring the consumption 
of energy [122]. Consistently, analysis of transcriptional changes downstream of WNT 
signaling suggest it plays a role in glutamine metabolism [123], which is important in cell 
growth and biosynthesis [124, 125]. In the immune response, upregulation of energetic 
pathways is important, but efficient utilization of energy towards initiating and sustaining 
inflammation precedes the need for cell growth and biosynthesis. There is limited data on the 
role of WNT/β-catenin signaling in macrophages, though a few studies exist. In alveolar 
macrophages, WNT/β-catenin has been implicated as a causative factor in excess fibrosis, 
which may be due to WNT/β-catenin mediated M2 macrophage polarization [126, 127].  
 
1.3 HOMEOSTATIC CELLULAR FUNCTIONS INVOLVED IN INNATE 
IMMUNITY 
In additional to the specialized mechanisms of innate immune cells to respond to 
immunogens, these cells also have a complex set of adaptive mechanisms to maintain cellular 
homeostasis. These mechanisms are shared among all cells and are especially prominent 
during conditions of cell stress. They function to either facilitate a return to homeostasis or 
delete severely dysregulated cells in order to maintain health of the organism [128]. These 
cell stress responses have both cell-autonomous and cell-extrinsic components, the latter of 
which contributes to systemic adaptations to stress conditions. Along this line of thinking, 
inflammation has been described as a part of a spectrum, with bona-fide systemic 
inflammation being the extreme end of a progressive spectrum that includes homeostasis, the 
physiological stress response, and finally inflammation [129]. Consistently, conditions that 
activate innate immunity including the presence of PAMPs or DAMPs can be considered 
intense forms of cell stress [130].  
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Two such conditions that are adaptive responses to disruption of cellular homeostasis are 
autophagy and programmed cell death. Autophagy is a critical mechanism for the clearance 
of cytoplasmic waste and is considered an adaptive mechanism as it recycles cellular 
nutrients during conditions of cell stress. It has also been implicated in the clearance of 
intracellular pathogens, which is important for defense against a variety of bacterial infections 
[131]. Programmed cell death (PCD) occurs when cellular homeostatic mechanisms are 
overcome. PCD can be anti-inflammatory in nature (apoptosis) or inflammatory (necroptosis, 
pyroptosis, etc) [132, 133]. In this section, I discuss the autophagy/lysosome system, its role 
as part of the stress response, and its contribution to innate immunity. I then move on to 
discuss the several PCD pathways, with emphasis on how they affect inflammation. The 
work in this thesis involves signaling controlling these pathways and their effects on innate 
immunity. 
 Autophagy/Lysosome System 
Autophagy is a conserved cellular degradation pathway involved in the clearance of 
cytoplasmic waste. It delivers both cellular organelles and large protein complexes to the 
lysosome, enabling their destruction. From an evolutionary perspective, autophagy developed 
both as an adaptive mechanism mediating cellular recycling and a quality control mechanism 
for the clearance of harmful complexes [134]. Autophagy is orchestrated by complex 
mechanisms involving more than 30 proteins. Upon induction, a membrane sac termed the 
isolation membrane expands into a double membrane vesicle termed the autophagosome. 
Elongation of this membrane results in either the selective or nonselective envelopment of 
cytoplasmic constituents, which are then confined in the autophagosome lumen. The 
autophagosome eventually merges with a lysosome, resulting in a structure called the 
autophagolysosome which mediates the destruction of sequestered material via lysosomal 
proteases and the acidic pH of the compartment [135].  
Though autophagy was initially recognized as a cellular response to nutrient starvation, it is 
now appreciated that autophagy is induced by many cell stress events. Immunologic stimuli 
are among those that induce autophagy, including stimulation with LPS. LPS stimulation 
activates TLR4, resulting in the targeting of Beclin-1 (a key component of the Class III 
PI(3)K autophagosome initiation complex) to the TLR adaptor proteins MyD88 and TRIF, 
which results in its TRAF6 mediated K63-linked ubiquitination and activation [136, 137]. 
Autophagy is also initiated following pathogenic invasion by many protozoa, bacteria, and 
viruses. Autophagy mediates immunity against intracellular pathogens by direct sequestration 
of pathogens, delivering them to the lysosome for destruction [131]. The importance of 
autophagy in the immune response is further highlighted by its function in antigen 
presentation [138]. While the complex mechanisms that regulating autophagy initiation are 
out of the scope of this thesis, it has recently been appreciated that autophagy is also 
transcriptionally controlled by Transcription Factor EB (TFEB).  
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 Programmed Cell Death 
PCD is a critical process for normal cell turnover, organismal development, and immune cell 
function. Canonically, PCD was believed only to occur through apoptosis, a caspase-
dependent process resulting in non-inflammatory cell death. Inflammatory cell death is 
characterized by cellular leakage, cytoplasmic granulation, and organelle/cellular swelling 
(oncosis) and is termed necrosis. It was long assumed that necrotic cell death was accidental, 
due to the inability of cells to respond appropriately to cellular injury or stress. Accumulation 
of evidence over the years has challenged the view that necrosis only occurs accidently, 
leading to the understanding that regulated forms of necrosis exist [139-141]. It is now 
appreciated that there are multiple PCD pathways resulting in necrotic cell death, including 
necroptosis, pyroptosis, ferroptotis, MTP-mediated regulated necroptosis, parthanatosis, and 
NETosis/ETosis. All of these forms of PCD have different regulatory factors, execution 
factors, and physiologies [139-141]. Of these, necroptosis and pyroptosis are the best 
understood. As necroptotic and pyroptotic cell death result in the release of inflammation 
inducing DAMPs and are investigated later in this thesis, their basic mechanisms and 
signaling paradigms are discussed. 
1.3.2.1 Apoptosis 
Apoptosis, which was first described in a classic 1972 paper by Kerr, Wyllie, and Currie 
[142], is a morphologically distinct cell death characterized by cell shrinkage, an intact 
membrane that has undergone blebbing, cytoplasmic retention in apoptotic bodies, and 
nuclear DNA fragmentation [143]. The molecular machinery involved in apoptosis was first 
elucidated in C. elegans [144] and later worked out in mammals [145]. In short, members of 
the caspase family involved in apoptosis have been classified as initiator caspases (caspase-8, 
-9, and -10) or executioner caspases (caspase-3, -6, and -7). Both the extrinsic and intrinsic 
apoptosis pathways converge at activation of the executioner caspases, but upstream 
signaling differs. The extrinsic pathway is caspase-8 dependent and responds to FasR death 
signals, while the intrinsic pathway is caspase-9 dependent and responds to intracellular 
stresses (e.g. toxins, hypoxia, radiation) [143, 146]. Notably, apoptosis is considered a non-
inflammatory form of cell death, as cell components remain neatly packaged inside apoptotic 
bodies precluding the release of DAMPs into the surrounding microenvironment [147]. 
Additional mechanisms exist to contain a potential inflammatory response, including “find 
me” and “eat me” signals on apoptotic bodies that recruit phagocytes facilitating their 
clearance [148]. Moreover, apoptotic cells and/or the phagocytes that clear them release anti-
inflammatory cytokines such as IL-10 and TGF-β, ensuring minimal inflammatory responses 
in physiological conditions [147]. 
1.3.2.2 Necroptosis 
Necroptosis refers to a form of programmed necrosis, which is an inflammatory cell death. 
The existence of programmed necrosis pathways was first suggested by Goodling’s group, 
who observed that TNF-α could induce both apoptosis and necrosis [149]. The authors used 
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two different cell lines sensitive to TNF-α mediated death, F17 (rat fibroblast line) and L-M 
(mouse fibroblast cell line), to examine the biochemical and morphological features 
associated with TNF-α induced death. The F17 cell line displayed apoptotic death, with low-
molecular weight DNA and membrane blebbing seen by time-lapse microscopy (hallmarks of 
apoptosis). The L-M cell line, on the other hand, had no detectable low-molecular weight 
DNA release, and showed cellular swelling, cytoplasmic granulation, and eventual lysis by 
time lapse microscopy. This led the authors to suggest the potential formation of a “self-
assembling membrane attack complex” a statement proven true more than 20 years later with 
the discovery of the necroptotic pathway [150]. 
The cellular signaling pathways mediating necroptosis have now been partially elucidated. 
Necroptosis is a RIPK1, RIPK3, and MLKL dependent pathway that is initiated by ligands of 
the death receptor family [151, 152]. Upstream activation requires RIPK1 kinase activity, 
which acts a molecular switch between proliferation/inflammation (RIPK1 complex 1 activity 
– NFkB activation) and necroptosis (RIPK1 complex 2b activity – programmed cell death). 
Initiation of necroptosis leads to trimerization of RIPK3, resulting in membrane recruitment 
of the effector protein MLKL which leads to formation of membrane holes and cell death 
[153]. Interestingly, basal levels of caspase-8 decrease RIPK1 kinase activity, indicating 
crosstalk between apoptotic and necroptotic PCD pathways. Necroptotic proteins are highly 
expressed in macrophages, which have been shown to undergo necroptosis in physiological 
conditions. Necroptosis is considered an inflammatory cell death pathway, as necrotic cell 
death results in the release of several DAMPs due to loss of membrane permeability [154]. 
There is also evidence suggesting that necroptotic death activates low levels of cytokine 
transcription in dying cells [155]. 
1.3.2.3 Pyroptosis 
Pyroptosis is a highly inflammatory programmed cell death pathway that occurs following 
inflammasome activation. In short, activation of caspase-1 by inflammasome assembly 
results in cleavage of gasdermin D, allowing the N-terminal of gasdermin D to translocate to 
the plasma membrane and form pores [156]. The formation of membrane pores results in the 
release of several DAMPs, including ATP, DNA, ASC specks, the HMGB1 protein, and IL-
1β, which strongly propagates inflammation [157].  
 
1.4 LRRK2 
Several non-receptor proteins were identified as novel signaling molecules downstream of the 
receptors investigated in this thesis, the Leucine-rich repeat kinase (LRRK2) is one of them. 
Thus, I provide essential background on the structure, biological function, and immunological 
functions of the LRRK2 protein. 
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 LRRK2: Background 
Leucine-rich repeat kinase 2 (LRRK2) is a large, 2527 amino acid protein with multiple 
functional and protein interaction domains. Autosomal dominant mutations in LRRK2 are the 
most common genetic cause of Parkinson’s disease (PD) and result in late onset disease that 
is symptomatically indistinguishable from idiopathic PD [158]. LRRK2 mediated and 
idiopathic PD share common pathophysiologic pathways, including immune system 
involvement [159, 160]. In addition to PD, LRRK2 has been identified as a risk factor for 
Crohn’s disease and leprosy [161, 162]. The common link between these diseases is systemic 
inflammation [163], further implicating LRRK2 in peripheral and innate immunity. Despite 
the vast body of research on neuronal LRRK2 (where it is lowly expressed), its physiological 
function remains unknown [164]. As LRRK2 is most strongly expressed in myeloid cells and 
B-lymphocytes [165], focus has turned to the role of LRRK2 in the immune system in hope 
of further elucidating its physiological and pathophysiological roles.  
 LRRK2: Structure and Function 
LRRK2 is a large Roco family protein containing putative protein-protein interaction 
domains flanking a central catalytic region. Its core catalytic region consists of an N-terminal 
Ras-of-Complex (ROC) GTPase domain, a C-terminal serine/threonine kinase (MAPKKK-
like, RIPK-like) domain, and a linker C-terminal of Roc (COR) domain. The N terminal of 
LRRK2 has an LRR (leucine rich repeat) domain and an ankyrin domain, while the C 
terminal contains WD40 repeats [166]. In line with its many protein interaction domains, a 
recent computational review of the literature shows more than 200 interaction partners for 
LRRK2 [167]. Given that multiple LRRK2 domains also have enzymatic activity, its 
structure suggests a multifaceted involvement in cell signaling and molecular scaffolding, 
implicating it as a potential regulatory hub with the ability to integrate and modulate multiple 
signaling pathways. 
LRRK2 exists primarily as a cytosolic monomer, but in certain conditions forms dimers on 
the plasma membrane resulting in significant enhancement of kinase activity [168-170]. 
Recent advances have provided structural insight into the domain interactions mediating 
LRRK2 dimerization. Guaitoli et al. show that two monomers symmetrically interact in a 
head-to-tail orientation, with intramolecular interactions between the N-terminal ankyrin 
domain and C-terminal WD40 domain necessary for stabilization of intermolecular 
interactions by the central ROC-COR regions allowing dimer formation [171]. There is 
considerable evidence that LRRK2 undergoes autophosphorylation, with many of these 
events occurring in the ROC domain and regulating the ROC domain’s GTPase activity [172, 
173]. This observation raises the important point that LRRK2 catalytic domains likely 
regulate each other. Another study linked GDP/GTP binding state to dimerization in a 
LRRK2 homologue [174]. The study shows that a bacterial LRRK2 homologue is mainly 
dimeric in the unbound or GDP-bound state, but forms monomers upon GTP binding, 
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indicating a monomer-dimer 
cycle during GTP binding and 
hydrolysis [174]. Together, 
these findings suggest a 
complex mechanism by which 
LRRK2 kinase activity 
modulates its GTPase activity, 
which in turn regulates dimer 
formation and kinase activity 
(Figure 1). These important 
findings have significant 
implications in our attempt to 
better understand the pathogenic 
properties of disease causing 
LRRK2 mutants.  
The majority of PD causing LRRK2 mutants are in the core catalytic region [175]. The most 
common pathogenic mutation, G2019S, and the neighboring I2020T mutation are both in the 
kinase domain and increase kinase activity [176-178]. The increase in LRRK2 kinase activity 
appears to be sufficient for its pathogenic effects, as inhibition of kinase activity in these 
mutants slows LRRK2 mediated pathology [179]. The ROC domain of LRRK2 has high 
homology to Ras superfamily proteins and therefore both binds and hydrolyzes GTP [166]. 
The R1441 location in ROC domain is a hotspot for pathogenic mutations, as changes to 
C/G/H are all pathogenic [179]. It is unclear if mutations at this location increases kinase 
activity, but ROC domain autophosphorylation is clearly increased in these pathogenic 
mutants, as is similarly seen with increased kinase activity. 
Finally, while many substrates for LRRK2 have been suggested, it is unclear which are 
physiological substrates due to many studies being done in overexpression models in vitro 
[180-183]. Recently, an unbiased screen found Rab1, Rab8a, Rab10 as bona-fide in vivo 
substrates of LRRK2 [184], and a second report corroborated that LRRK2 phosphorylates 
membrane bound Rabs [185, 186]. Moving forward, more research needs to be done to 
determine the pathophysiological consequences of Rab substrate hyperphosphorylation. 
Given the involvement of Rab proteins in membrane dynamics, it is possible that the 
pathogenic effects of LRRK2 are mediated by disruption of membrane associated pathways, 
including the autophagy/lysosome system. 
 LRRK2: Effects on the Autophagy/Lysosome Pathway 
Although LRRK2 was linked to the endolysosomal system and autophagy almost 10 years 
ago [187], there is still no consensus on the effect of LRRK2 on these pathways. There exist 
many discordant reports within the field, with studies showing both positive and negative 
effects of LRRK2 on autophagy, a role for LRRK2 in different steps along the autophagic 
pathway, and discrepancies between the effects of LRRK2 kinase inhibition, 
Figure 1. Schematic representation of hypothesized cross-
regulation between LRRK2 kinase and GTPase activity. 
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knockdown/knockout, and LRRK2 mutant expression (reviewed in [188, 189]). Here, I 
briefly summarize the existing data categorized by the biochemical approached used to study 
LRRK2: (1) LRRK2 G2019S mutant, (2) LRRK2 knockdown or KO, or (3) pharmacological 
LRRK2 kinase inhibition.  
The pathogenic effects of LRRK2 G2019S are thought to be mediated primarily by an 
increase in kinase function – thus the G2019S mutant is often used to model LRRK2 kinase 
overactivity. Many studies on the LRRK2 G2019s mutation have shown it as a positive 
regulator of autophagy [187, 190-195]. Overexpression of LRRK2 G2019S in a neuronal cell 
line caused an increase in autophagosomes and neurite shortening [187]. Later studies 
overexpressing the LRRK2 kinase domain (WT and G2019S) corroborate this, showing 
increases in autophagosome number dependent on a CaMKK-β/AMPK and an NAADP 
dependent pathway [190]. Several other studies suggest LRRK2 G2019S as a positive 
regulator of autophagy; one reported enhanced autophagy due to LRRK2 G2019S 
phosphorylation of Thr56 on Bcl-2 [191], another showed increased in basal autophagy in 
LRRK2 G2019S patient fibroblasts [194], and yet another showed increased autophagosome 
formation in the cerebral cortex [195]. On the other hand, a study on LRRK2 G2019S patient 
derived stem cells suggested a decrease in autophagic flux despite increased autophagosome 
formation due to defects in autophagosome clearance [196]. This data is consistent with other 
reports showing defective lysosome degradation in LRRK2 G2019S cells [192, 193]. Studies 
from the Manzoni and coworkers suggest decreased autophagy/autophagic flux in G2019S 
cell lines and patient fibroblasts [197, 198]. Given the conflicting studies, there is a need for 
more reproducible data and better mechanistic insights on the effects of LRRK2 G2019S on 
autophagy. 
Studies in LRRK2 KO models again show a complex picture. In LRRK2 KO mice, 
autophagic changes in kidney tissues were age dependent. Seven month old mice showed 
increased autophagy in the kidneys, while twenty month old mice showed the opposite [199]. 
An elegant study using LRRK2 knockdown macrophages provided some mechanistic insight 
into the role of LRRK2 in autophagy after LPS stimulation. LPS stimulation induced 
phosphorylation of LRRK2 at Ser935 and initiated the recruitment of LRRK2 to membranes; 
macrophages deficient in LRRK2 show less autophagosome formation and autophagic flux 
than controls [200]. Finally, a study using LRRK2 KO neuronal cells showed defects in 
autophagy dependent on endophilin A function, which LRRK2 directly phosphorylates [180, 
201].  There have been a variety of studies using LRRK2 chemical inhibitors, with studies 
from Manzoni and coworkers showing an increase in autophagy after kinase inhibition [197, 
202]. Studies using these chemical inhibitors are hard to interpret, as they effectively inhibit 
kinase activity but do not affect LRRK2 scaffolding or GTPase activity. Without chemical or 
biochemical tools to selectively inhibit other LRRK2 functions, studies using existing 
chemical inhibitors should be interpreted carefully.  
Given the complexities and conflicting data, it is likely that we are missing a key mechanistic 
feature related to the effect of LRRK2 on autophagy. However, there do exist several valid 
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reasons that data on LRRK2 in autophagy appears discordant. First, there may be cell type 
differences stemming from variation in LRRK2 expression level from cell to cell and from 
variation in basal autophagy among cell types. Second, LRRK2 may affect multiple steps in 
the autophagy/lysosome pathway, with different phenotypes resulting from overexpression or 
loss of function. Finally, LRRK2 may differentially regulate autophagy dependent on the 
upstream stimulus, forming different complexes in response to different stimuli. In sum, 
while it is accepted in the scientific community that LRRK2 modulates the 
autophagy/lysosome pathway, detailed and reproducible studies on the effect of LRRK2 on 
each step of the autophagy/lysosome system are needed. 
 LRRK2: Role in the Immune System 
Several lines of evidence exist suggesting an immune function for LRRK2. First, LRRK2 is 
most highly expressed in myeloid cells and B-cells [165]. In macrophages, its expression is 
upregulated by IFN-γ and viral particles [165, 203, 204], and LRRK2 is phosphorylated at 
Ser935 upon exposure to LPS [205]. Structurally, the LRR repeats on LRRK2 resemble those 
seen on PRRs (such as the TLRs and NLRs), and structural analysis shows that LRRK2’s 
LRR domain resembles that of NLRP3 [206]. The LRRK2 kinase domain is a RIPK family 
member, and this family of proteins is intimately related to inflammation and cell death [151, 
207, 208]. RIPK1 and RIPK3 act as molecular switches between inflammatory and 
necroptotic signaling [151]. RIP2 functions downstream of the PRRs NOD1/NOD2, and 
LRRK2 has been implicated in the NOD2/RIPK2 pathway as it directly interacts with these 
proteins. This interaction is required for the proper release of bacterial lysozyme in Paneth 
cells of the gut in response to commensal bacteria [209].  
A variety of studies have shown that LRRK2 deficiency generally increases susceptibility to 
intracellular bacterial infection, with focus on the role of LRRK2 in macrophages [165, 209, 
210]. Mice deficient in LRRK2 showed increased susceptibility to Salmonella Typhimurium 
[210], while in vitro infection of LRRK2 deficient macrophages with Salmonella reveal 
defects in bacterial killing [165]. LRRK2 deficient mice also show increased susceptibility to 
Listeria infection [209]. Finally, LRRK2 mediated changes in autophagy are likely to have 
important consequences on pathogen clearance, as autophagic engulfment of foreign 
pathogens (called xenophagy) is an important mechanism in maintaining host homeostasis 
[131]. Overall, these studies suggest that LRRK2 is a proinflammatory protein, and that lack 
of LRRK2 increases susceptibility to foreign pathogens. 
Consistent with the notion that LRRK2 is a positive regulator of inflammation, several 
studies suggest that LRRK2 deficiency rescues pathogenicity caused by aberrant host 
inflammation [211-216]. In a murine model of neuro-HIV, LRRK2 kinase inhibition and 
LRRK2 deficiency decreased pathological inflammation after phagocytosis of the HIV-
protein Tat [211, 212]. Two additional studies in LRRK2 deficient microglia showed an 
attenuation of proinflammatory signals, including TNF-α and iNOS after LPS stimulation 
[213, 214]. Moreover, LRRK2 pathogenic mutants appear to be proinflammatory, with the 
R114G KI mice having increase inflammatory markers and LRRK2 G2019S myeloid cells 
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showing increased migration to cytokines [215, 217]. Finally, asymptomatic patients with the 
LRRK2 G2019S mutation show increases in peripheral inflammation, including increases in 
IL-1β, IL-8, and other proinflammatory markers [216].  
Apart from myeloid cells, LRRK2 is highly expressed in DCs and B-cells. In DCs, LRRK2 
was shown to regulate expression of the Na+/K+ ATPase and Na+/Ca2+ pumps in the plasma 
membrane [218, 219]. This results in LRRK2 KO cells having increased calcium 
mobilization upon store operated calcium entry from the ER. In B cells, LRRK2 is expressed 
in B-2 cells but not B-1 cells [220]. A preliminary immunophenotyping of the B cell 
compartment in LRRK2 KO mice showed increased basal IgA levels and increased IgM after 
immunization with TNP-Ficoll [221, 222]. A more recent study implicated LRRK2 function 
in B cells to systemic erythematous lupus (SLE) [223]. LRRK2 was shown to promote 
autoantibody production in a pristine induced SLE model, and LRRK2 KO mice were 
protected against development of disease. Accordingly, LRRK2 KO mice showed decreased 
germinal center and plasma cell levels basally [223].  
 
1.5 TRANSCRIPTION FACTOR EB (TFEB) 
TFEB is the master transcriptional regulator of the autophagy/lysosome machinery and an 
integral component of the cell stress response. The autophagy/lysosome system and its role in 
cellular stress is investigated several times in this thesis, and TFEB is implicated downstream 
of a variety of signaling pathways. Thus, I provide necessary background on this essential 
transcription factor. 
 TFEB: Background 
TFEB is an evolutionarily conserved transcription factor belonging to the microphthalmia 
(MiT) family of proteins, which include the closely related transcription factors MITF, TFE3, 
and TFEC. TFEB is the master transcriptional regulator of the autophagy and lysosome 
machinery [224], and shares some functional overlap with TFE3 which has also been shown 
to regulate the autophagy/lysosome machinery [225]. TFEB has been implicated in the 
pathogenesis of several cancers and pursued as a therapeutic target for the treatment of 
several diseases resulting from accumulation of toxic aggregates [226]. While previously 
thought to be a static housekeeping organelle, it is now appreciated that the lysosome is 
tightly regulated by both transcriptional activators and repressors [227-229]. TFEB was first 
described as a response to nutrient deprivation, as starvation promotes mTOR dependent 
TFEB nuclear translocation [230]. Once in the nucleus, TFEB binds a 10-base palindromic 
sequence (GTCACGTGAC) called CLEAR binding elements resulting in the transcriptional 
upregulation of TFEB response genes, including those of the autophagy/lysosome system 
[228]. Via these pathways, TFEB promotes the clearance of aggregated proteins, which has 
therapeutic implications [231-235]. In addition to its function on the autophagy/lysosome 
system, TFEB regulates endosome dynamics and lysosomal exocytosis [224]. TFEB also 
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promotes transcription of several immune genes and those that function as part of the 
integrated stress response [236, 237].  
 TFEB: Molecular Mechanisms of Activation 
TFEB is regulated primarily by post translational modifications, as it contains many 
phosphorylation sites governing its protein-protein interactions and subcellular localization 
(reviewed in [224]) (Figure 2). TFEB was first described as an adaptive response to nutrient 
starvation, which causes its nuclear translocation and the transcription of autophagy related 
genes to promote nutrient recycling [228]. The mammalian target of rapamycin complex 1 
(mTORC1) is an essential nutrient sensor responsible for integrating environmental signals 
[238]. The mTORC1 complex contains the important kinase mTOR, which was quickly 
determined to regulate TFEB subcellular localization by directly phosphorylating TFEB 
Ser211 [239]. In nutrient replete conditions, mTOR-dependent phosphorylation of TFEB on 
Ser211 mediates its interaction with 14-3-3 proteins, resulting in its cytoplasmic sequestration 
and inactivation [240, 241]. Inhibition of mTOR in nutrient starved conditions conversely 
results in the dephosphorylation of Ser211, freeing TFEB from interaction with 14-3-3 proteins 
and allowing its nuclear translocation [228]. More recently, it was shown that mTORC1 is 
also responsible promoting TFEB cytoplasmic sequestration by phosphorylating TFEB on 
Ser122 [242]. 
The discovery of mTOR independent TFEB activation pathways led to the hypothesis that 
additional mechanisms regulate TFEB Ser211 phosphorylation. Calcineurin, a heterodimer 
consisting of the calmodulin-binding catalytic subunit calcineurin A and a smaller Ca2+-
binding subunit calcineurin B, was subsequently identified as the phosphatase responsible for 
dephosphorylating Ser211. Under certain conditions, including starvation, ER stress, and ROS 
exposure, calcineurin is activated by a Ca2+ signal allowing the dephosphorylation of Ser211 
and subsequent nuclear translocation of TFEB [236, 243, 244]. The source of the Ca2+ signal 
responsible for calcineurin activation has been hotly debated, though it is now understood 
that Ca2+ mobilization from a variety of sources can activate TFEB. In the context of TFEB 
activation following nutrient starvation, lysosomal Ca2+ released through MCOLN1 has been 
implicated as the Ca2+ source. Ca2+ release via MCOLN1 was later found to be important for 
TFEB nuclear translocation following ROS exposure and Fc-mediated phagocytosis [243-
245]. A more recent study definitively showed that TFEB activation also occurs upon 
calcium release from the ER and mitochondria following pharmacological stimulation with 
known TFEB activators, underscoring the importance of Ca2+ mobilization in TFEB 
activation [246]. 
There are a variety of mTOR independent pathways that regulate TFEB nuclear translocation, 
stability, and activation status. Ser142 is phosphorylated by ERK1/2 promoting its cytoplasmic 
sequestration [247]. Recently, GSK3β and Akt were shown to be important kinases 
controlling TFEB [248, 249]. GSK3β phosphorylates TFEB on Ser134 and Ser138, sites that  
 
 22 
 
are important in directing TFEB to the lysosome surface enabling mTOR phosphorylation 
[248]. Protein kinase C (PKC), which is upstream of GSK3β, is an important signaling 
molecule controlling activation of this pathway, and pharmacological manipulation of PKC 
has proven to be an effective method to stimulate TFEB activity [248]. The C-terminus of 
TFEB contains a serine rich region with 5 phosphorylation sites. Akt phosphorylates TFEB 
on its C-terminus at Ser467, inhibiting its nuclear translocation [249]. Meanwhile, a previous 
study showed that PKCβ mediated C-terminal phosphorylation in osteoclasts resulted in the 
stabilization of TFEB and promoted its activity. Thus, more studies are needed to parse out 
the individual contributions of these C-terminal phosphorylation sites on TFEB activity. A 
summary of TFEB phosphorylation sites and the kinases involved are illustrated 
schematically (Figure 2). 
 
 TFEB: Role in the Cell Stress Response 
While TFEB was first discovered as a response to starvation, it is now clear that TFEB 
responds to a variety of cellular stresses (reviewed in [250]). TFEB activation is believed to 
be an adaptive response to cell stress, as it results in the upregulation of transcriptional 
networks that maintain cellular homeostasis in the face of the environmental stress sensed. 
Figure 2. Schematic illustration of TFEB phosphorylation sites and implicated kinases. Red = 
inhibitory, green = activating. Figure originally published in Nabar and Kehrl, Yale J Biol Med, 
2017, 90(2): 301-315. 
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TFEB is strongly activated in response to lysosomal stress, which physiologically occurs 
when the autophagy/lysosomal system is unable to maintain homeostasis resulting in an 
inability to properly degrade cellular waste [228, 241, 251]. In response, TFEB activates 
transcriptional networks that promote lysosomal biogenesis and autophagy to maintain 
protein homeostasis during lysosome stress conditions.. 
TFEB also responds to mitochondrial stress, as it activated after induction of mitophagy or 
treatment with mitochondrial membrane permeabilizers [244, 252]. In response, TFEB 
upregulates autophagy machinery which helps remove damaged mitochondria via mitophagy, 
and transcriptionally activates PGC-1α which promotes mitochondrial biogenesis [253]. 
Additionally, TFEB functions as an integral component in the unfolded protein response in 
conditions of ER stress [236]. In this scenario, TFEB activates ATF4 and CHOP, which 
promote cell survival. Activation of the autophagy/ lysosome pathway promotes clearance of 
unfolded proteins which accumulate after ER Stress, further helping maintain homeostasis. 
Finally, TFEB has also been implicated in genotoxic and oxidative stress. In conditions of 
genotoxic stress such as DNA damage, TFEB amplifies the p53 dependent response to 
coordinate cell cycle check points and cell death pathways [254]. In oxidative cell stress 
conditions, TFEB is activated in an mTORC1-independent fashion, which may have 
implications in cell growth during immune activation and cancer [255].  
 TFEB: Immune function 
Considering the role of TFEB in the cell stress response, it is unsurprising that it is implicated 
in immune function. Pathogenic invasion itself can be considered a type of cell stress and is 
known to activate a variety of homeostatic cell stress pathways. However, evolutionary 
analysis of TFEB homologues suggest a larger role for TFEB in the immune response than 
expected. The Caenorhabditis elegans TFEB homologue HLH-30 transcriptionally controls 
80% of immune genes in the worm [256]. HLH-30 is strongly activated in response to 
Staphylococcus aureus, and loss of HLH-30 greatly decreases worm tolerance to infection. 
Interestingly, C. elegans does not contain the critical immune transcription factor NFκB, 
while mammalian species do. It is likely that with the evolutionary emergence of NFκB, 
specialization of transcription factor functions resulted in HLH-30 homologues losing 
transcriptional control of certain immune genes while maintaining control of others. A recent 
study using TFEB, TFE3, and TFEB/TFE3 double KOs convincingly showed direct TFEB 
binding to immune gene promoters and an associated increase in immune related gene 
transcription. Specifically, they show that TFEB is upregulated in response to macrophage 
activation, and that macrophages lacking TFEB/TFE3 have decreased CSF2, IL-1β, IL-2, and 
CCL2 at the protein and transcript level. Finally, CHIP-seq experiments in this study showed 
that TFEB binds CLEAR sequences in many immune response genes, though they typically 
bind farther from the promoter than seen for lysosome/autophagy genes [237].  
In addition to direct transcriptional activation of immune genes, many cellular processes 
controlled by TFEB are important in the immune response, including autophagy (for 
intracellular pathogen degradation), vesicle dynamics (for phagocytosis and antigen 
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presentation), and lysosomal exocytosis (for signal secretion). TFEB has been shown to be 
activated by a variety of immune receptors and aid in the clearance of several pathogens. For 
example, IFN-γ results in the calcineurin mediated nuclear translocation of TFEB, which is 
importance in the clearance of Mycobacterium tuberculosis [257]. Upon infection with 
Staphylococcus aureus, activation of an unknown GPCR leads to Gαq coupling and 
phospholipase C mediated calcium mobilization, promoting TFEB activation. A study from 
our group showed that AGS3 is an essential regulator of TFEB [73]. Macrophages from 
AGS3 KO mice are more susceptible to infection by intracellular bacteria, including 
Mycobacterium Tuberculosis, methicillin resistant Staphylococcus aureus (MRSA), and 
Burkholderia cenocepacia, underscoring the role of TFEB in intracellular infection.  
TFEB has been shown to have cell specific functions in immune cells. In macrophages, in 
addition to being upregulated by LPS [237], TFEB is strongly activated in response to Fc-
Receptor mediated phagocytosis [245]. Functionally, TFEB is involved in the production of 
ROS in the phagosome upon Fc-receptor mediated phagocytosis, and silencing TFEB results 
in bacterial killing defects [245]. Several studies have suggested a role for TFEB in 
macrophage polarization, showing that TFEB activation biases macrophages towards an M1 
phenotype [258-260]. The first study showed that TFEB is downregulated in tumor 
associated macrophages (TAMs) by signals in the tumor microenvironment, causing 
polarization towards an M2 phenotype [260]. The next study showed that TFEB is required in 
reprogramming TAMs back to an M1 phenotype during treatment with chloroquine, as TFEB 
promotes the glycolytic metabolic switch critical to M1 polarization [258]. Finally, a third 
study showed that Lamptor1 KO myeloid cells results in hyperactivation of TFEB, and 
myeloid-specific Lamptor1 conditional KO mice are hypersensitive to LPS [259].  
In dendritic cells, TFEB has been shown to play an important role in antigen presentation. 
Lysosomal signaling is important in cross presentation; high levels of lysosome degradation 
promote less cross presentation and MHC Class II signaling, while low lysosome degradation 
levels enhance cross presentation [30]. TFEB acts as a molecular switch in dendritic cells and 
can either inhibit or promote cross presentation in different conditions [261]. Finally, TFEB 
has been shown to regulate dendritic cell migration by modulating cytoskeletal organization 
after bacterial sensing [262]. Much less is known about the function of TFEB in lymphoid 
cells.  It has been shown that TFEB is upregulated upon T-cell receptor (TCR) ligation in T-
cells, and that TFEB is required for CD40L expression on T-cells [263]. The role of TFEB in 
B cells remains unclear, and merits rigorous investigation moving forward.
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2 AIM 
The aim of this thesis was to elucidate molecular mechanisms by which cells of innate 
immunity transduce and integrate extracellular signals to generate a coordinated biological 
response. 
The specific aims were: 
Paper I. To investigate the role of Gαi signaling in macrophage polarization and describe its 
effects on inflammasome activation and cytokine release. 
Paper II. To investigate the signaling pathways through which the cell surface receptor CD38 
and the large kinase LRRK2 regulate autophagy in macrophages. 
Paper III. To investigate the mechanisms mediating cross-talk between the cell stress 
response transcription factor TFEB and the proliferative Wnt signaling pathway. 
Paper IV. To investigate the cellular mechanisms by which the SARS-CoV ORF-3a 
potentiates aberrant inflammation. 
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3 RESULTS AND DISCUSSION 
3.1 GαI2 REGULATES INFLAMMASOME PRIMING AND CYTOKINE RELEASE 
BY BIASING MACROPHAGE POLARIZATION (PAPER I) 
Macrophages can be broadly categorized as proinflammatory M1 or anti-inflammatory M2 
macrophages, and signaling from the microenvironment plays an important role in 
influencing their phenotype [264]. Gαi2 and Gαi3 are highly expressed in murine macrophages 
[67], and Gαi signaling has previously been shown to regulate macrophage chemotaxis, 
phagocytosis, and activation [67, 83, 265]. Given that the aim of this study is to characterize 
pathways by which innate immune cells transduce cellular signals into biological responses, 
and that the role of G-protein signaling in macrophage polarization is unknown, we 
investigated whether Gαi biases macrophage phenotype determination [266].  
To test this hypothesis, we first looked at 
IL-1β release following activation of 
various inflammasomes (NLRP3, AIM2, 
and NLRC4) in bone marrow derived 
macrophages (BMDMs) from several 
genetically modified mice. Gαi2 deficient 
BMDMs showed significant reductions in 
IL-1β release for all inflammasomes 
assayed (Figure 3A). BMDMs lacking 
Gαi3 showed no changes in IL-1β release 
in the same assays, indicating this 
phenotype is specific to the loss of Gαi2. 
We then used BMDMs derived from 
RGS-insensitive Gnai2G184S/G184S knock-
in (KI) mice to determine if excess Gαi2 
signaling caused reciprocal changes. 
Consistently, G184S KI mice had 
increased IL-1β release for all 
inflammasomes assayed (Figure 3B). 
We reasoned Gαi2 was unlikely to be affecting inflammasome assembly, as consistent 
changes were noted across all three inflammasomes despite different assembly mechanisms. 
Thus, we turned our attention to determining whether Gαi2 modulates the LPS priming phase 
or the IL-1β secretion phase. To do so, we mimicked signal 1 by stimulating with LPS and 
monitored TNF-α, IL-6, and IL-10 release by ELISA in Gαi2 deficient, G184S KI, and 
control BMDMs. IL-1β secretion is mechanistically distinct from secretion of other 
cytokines, thus changes in IL-1β without corresponding cytokine changes during priming 
indicates involvement of an IL-1β specific secretion mechanism. Conversely, changes in IL-
1β release with concomitant cytokine secretion changes during priming indicates involvement 
Figure 3. IL-1β release after activation of the 
indicated inflammasome in BMDMs generated 
from (A) WT and Gαi2 deficient or (B) WT and 
G184S KI mice. First published in Vural et al., J 
Immunol, 2019,  ji1801145.  
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of the LPS priming phase [58]. Gαi2 deficient cells showed decreases in TNF-α and IL-6, 
while reciprocal changes were observed in G184S KI BMDMs (Figure 4A, B). These results 
suggest that the IL-1β release defect observed in Gαi2 deficient BMDMs is due to defects 
during LPS priming. As pro- IL-1β transcriptional upregulation is controlled by the LPS 
priming phase, we immunoblotted for pro- IL-1β in Gαi2 deficient and G184S BMDMs, 
consistently noting decreased and increased expression respectively compared to the WT 
control after LPS stimulation (Figure 4C, D). 
 
Inflammasome priming is partially regulated by macrophage polarization [267]. Additionally, 
we noted increased IL-10 (an anti-inflammatory cytokine) despite decreases in TNF-α and 
IL-6 in Gαi2 deficient BMDMs, while G184S KI macrophages showed decreased IL-10 in the 
face of increased TNF-α and IL-6 secretion after LPS stimulation. Together, these 
observations prompted us to assay macrophage polarization by looking at important M1 
genes (iNOS, TNF-α, and IL-12p40) after M1 macrophage polarization with LPS and 
important M2 genes (Arg1, Fizz1, Ym1) after IL-4 mediated M2 polarization by qRT-PCR. 
Gαi2 deficient BMDMs showed decreased M1 gene expression after LPS mediated 
polarization and enhanced M2 gene expression following IL-4 mediated polarization, 
suggesting that loss of Gαi2 biases macrophages towards the M2 phenotype (Figure 5A, B). 
Similarly, G184S KI macrophages show increased M1 genes after LPS polarization and 
decreased M2 genes upon IL-4 stimulation, suggesting that enhanced Gαi2 signaling 
promotes the pro-inflammatory M1 phenotype (Fig 5C, D). We verified these results using a 
functional T-cell suppression assay, and as expected the M2 biased Gαi2 deficient BMDMs 
more effectively suppressed T-cell proliferation than control cells, while the opposite was 
true for G184S KI macrophages. 
Figure 4. Supernatant TNF-α, IL-6, and IL-10 levels in LPS stimulated BMDMs from (A) WT and Gαi2 
deficient and (B) WT and G184S KI mice. Immunoblots for pro-IL-1β following LPS stimulation for the 
indicated time in BMDMs from (C) WT and Gαi2 deficient and (D) WT and G184S KI mice. Adapted 
from figure first published in Vural et al., J Immunol, 2019,  ji1801145 
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Finally, we assessed the signaling pathways downstream of LPS and IL-4 in Gαi2 deficient 
cells to determine which signaling molecules may be involved. Gαi2 deficient BMDMs had 
defects in ERK1/2 and STAT3 signaling and enhanced Akt activation following LPS 
stimulation. After IL-4 stimulation, Gαi2 deficient BMDMs had enhanced STAT6 activation, 
which is important in M2 polarization. In sum, our study identified Gαi2 as a critical mediator 
of macrophage polarization. Excess Gαi2 signaling promotes an M1 pro-inflammatory 
phenotype, while a deficiency in Gαi2 promotes an M2 anti-inflammatory phenotype.  
 
3.2 CD38 SIGNALS THROUGH LRRK2 TO ACTIVATE TFEB (PAPER II) 
CD38 is an important cell surface receptor that is highly expressed on both B cells and 
macrophages [107]. In hepatocytes, it has been implicated as a positive regulator of 
autophagy through an NAADP-dependent pathway [104]. LRRK2, which is the most 
common genetic cause of PD, has also been implicated in autophagy and NAADP signaling 
[268]. In this paper we show that CD38 promotes the nuclear translocation of TFEB, the 
master transcriptional regulator of the autophagy and lysosome machinery, by a calcium 
signal that requires LRRK2. We then investigate the mechanisms through which this occurs 
in both macrophages and B cells. This paper again aims to elucidate signaling pathways from 
the cell surface that activate functions related to innate immunity, namely the transcriptional 
activation of the autophagy/lysosome system. 
Figure 5. A) Expression of M1 genes in Gαi2 deficient BMDMs after treatment with LPS. B) Expression of M2 
genes in Gαi2 deficient BMDMs after treatment with IL-4 C) Expression of M1 genes in G184S KI BMDMs 
after treatment with LPS D) Expression of M2 genes in G184S KI BMDMs after treatment with IL-4. Adapted 
from figure first published in Vural et al., J Immunol, 2019,  ji1801145 
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To first determine if CD38 activates TFEB, we stimulated B cells and macrophages with an 
α-CD38 monoclonal antibody (clone 90) and immunoblotted for TFEB after nuclear 
fractionation. Ligation of CD38 induced more than a two-fold increase in nuclear TFEB in 
both B-cells and macrophages. As CD38 generates several second messengers that mobilize 
calcium [89] and TFEB has previously been shown to be activated by calcium activated 
calcineurin mediated dephosphorylation [243], we determined whether CD38 mediated 
TFEB activation is calcium and calcineurin dependent. Immunostaining for endogenous 
TFEB in BMDMs showed that while CD38 ligation induces TFEB nuclear translocation, this 
is reversed both by calcium chelation and calcineurin inhibition (Figure 6A). Co-staining of 
CD38 1 hour after ligation with clone 90 shows a primarily intracellular pattern, indicating 
receptor internalization (Figure 6B).  
 
 
 
To validate that ligation of CD38 by clone 90 results in calcium mobilization, we measured 
calcium in real time after stimulation of both B cells and macrophages with clone 90. The 
observed calcium response was biphasic, with an initial sharp peak followed by a slower 
ramp phase (Figure 6C, black line). We used various inhibitors to determine the second 
messengers and calcium stores involved in this calcium signal. We determined that the initial 
sharp peak required NAADP and lysosomal calcium, while the slow ramp phase required 
Figure 6. (A) Immunostaining of endogenous TFEB after clone 90 stimulation with or without 
pretreatment with EGTA-AM and calcineurin inhibitors. (B) Immunostaining to show CD38 
localization after stimulation with clone 90. (C, D) Real time calcium assays measuring cytosolic 
calcium after clone 90 stimulation with or without indicated inhibitors. 
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extracellular calcium (Figure 6C, D). Our results additionally showed that ER calcium stores 
contributed to cytosolic calcium increase during the slow ramp phase, suggesting that 
NAADP/lysosomal calcium induce calcium release from other stores through CICR. 
Together, this data shows that CD38 ligation drives TFEB nuclear translocation through 
NAADP-dependent calcium signaling. 
As LRRK2 has been previously implicated 
in NAADP-dependent calcium signaling, 
we tested whether CD38 mediated TFEB 
activation was dependent on LRRK2. In 
LRRK2 KO macrophages and B-cells, 
TFEB nuclear translocation was not 
observed following ligation of CD38 with 
clone 90. Using real time calcium assays, 
we verified that LRRK2 KO B-cells do not 
produce a calcium response following 
clone 90 ligation (Figure 7A) and note that 
pretreatment with a LRRK2 kinase 
inhibitor also ablates the calcium response 
seen after ligation of clone 90. To further 
verify the importance of LRRK2 kinase 
activity in mediating the calcium response 
downstream of CD38, we performed the 
experiment in LRRK2 G2019S KI B-cells, 
which express a kinase overactive version 
of LRRK2 that is the most common 
pathogenic variant. The LRRK2 G2019S 
cells showed an enhanced calcium response 
compared to the WT cells (Figure 7B). 
Finally, we note that CD38 and LRRK2 
strongly interact by co-
immunoprecipitation and colocalize as 
discrete puncta on the cell membrane 
(Figure 7C). Taken together, these results 
suggest that LRRK2 is required for 
signaling downstream of CD38 ligation by 
clone 90, and that CD38 and LRRK2 form 
a complex at the plasma membrane.  
After elucidating the relationship between CD38 and LRRK2, we shifted our focus to 
determine if LRRK2 KO cells have TFEB activation defects. We find that LRRK2 KO 
macrophages fail to upregulate TFEB in response to LPS as seen in WT controls. 
Additionally, LRRK2 KO B-cells fail to upregulate TFEB following stimulation with B-cell 
Figure 7. Real time monitoring of cytosolic calcium 
following ligation of clone 90 in WT and (A) LRRK2 
KO and (B) LRRK2 G2019S KI B-cells. (C) Confocal 
imaging showing the colocalization of CD38 and 
LRRK2 on the plasma membrane.   
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activators. Finally, we show that overexpression of the kinase overactive LRRK2 G2019S 
results in the activation of TFEB, both by increasing its stability via phosphorylation on its C-
terminus and by driving its nuclear translocation in an NAADP-TPC2-lyosomal calcium 
dependent manner. This expectedly results in the transcriptional upregulation of TFEB target 
genes with corresponding increases at the protein level. In sum, in this paper we characterize 
a novel CD38-LRRK2-TFEB signaling pathway active in multiple types of immune cells. 
 
3.3 TFEB NEGATIVELY REGULATES WNT SIGNALING BY DIRECTLY 
BINDING β-CATENIN AND PROMOTING ITS DEGRADATION (PAPER III) 
The WNT signaling pathway is anabolic in nature, as it promotes cell growth, cell 
differentiation, and cell division [110]. These events require significant energy expenditure at 
the cellular level, and accordingly bioenergetic pathways are activated downstream of WNT 
signaling [123]. TFEB, on the other hand, is an adaptive cellular response that promotes 
nutrient recycling and preserves homeostasis. It is activated by various forms of cell stress to 
facilitate cell survival and prevent metabolic collapse [226]. TFEB belongs to the MiT family 
of proteins, which includes the closely related transcription factor MITF [225]. MITF has 
been implicated in augmenting WNT/β-catenin signaling, and additional crosstalk has been 
identified as WNT signaling reciprocally stabilizes MITF [269]. Despite the link between 
MITF and WNT signaling, the physiological and biochemical crosstalk between TFEB and 
WNT remains unknown. Given that cells have intricate crosstalk mechanisms to ensure 
downregulation of anabolic pathways during periods of stress [270], we hypothesized that 
TFEB may negatively regulate the WNT/β-catenin signaling pathway due to their opposing 
functional roles. 
 
Figure 8. Normalized Super 8x TOPFlash & Super 8x FOPFlash activity in (A) WT and TFEB 
KO 2393T cells transfected with the indicated proteins, and (B) WT 293T cells transfected with 
TFEB mutants restricting subcellular localization.  
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To test our hypothesis, we used CRISPR/Cas9 to generate TFEB KO HEK 293T cells. We 
generated 3 clones, and critical experiments were repeated in all clones to ensure the 
observed phenomenon were specific to the knockout of TFEB. First, we activated the 
WNT/β-catenin pathway by transfection of WNT3A and monitored TCF/LEF activity in WT 
and TFEB KO cells. In the absence of WNT signaling, no difference was observed between 
WT and TFEB KO cells. However, upon transfection of WNT3A, WT cells showed a 40-fold 
induction of luciferase activity, while TFEB KO cells showed more than a 200-fold 
induction. Indicating that the observed increase was specific to the loss of TFEB, 
reconstitution of TFEB KO cells with overexpressed TFEB reduced TCF/LEF activity by 
more than half (Figure 8A). This trend was preserved across all 3 TFEB KO clones, strongly 
suggesting that TFEB negatively regulates the WNT/β-catenin pathway in the WNT ON 
state. To determine the subcellular localization where TFEB exerts its influence on the 
WNT/β-catenin pathway, we monitored TCF/LEF activity after transfection with a either a 
control vector, WT TFEB, nucleus restricted TFEB (S211A), or cytoplasm restricted TFEB 
(R245-247A). In the WNT ON state, WT and nuclear TFEB reduced TCF/LEF activity 
compared to the control, but the cytoplasm restricted TFEB mutant was unable to do so 
(Figure 8B). This observation suggests that TFEB exerts its effects on the WNT/β-catenin 
signaling pathway in the nucleus. 
As β-catenin is critical for the activation of TCF/LEF target genes, we investigated whether 
TFEB regulates WNT signaling by interacting with β-catenin. We found that TFEB robustly 
interacts with β-catenin, and that this interaction is enhanced upon activation of WNT 
signaling. We then went on to show that TFEB and β-catenin interact in the nucleus, and that 
overexpression of TFEB reduces the β-catenin/TCF interaction (Figure 9A). This suggests 
that TFEB may competitively interact with β-catenin, decreasing its binding with TCF/LEFs. 
We then repeated the same experiment using WT and TFEB KO cells. We observed a 
stronger β-catenin/TCF interaction in TFEB KO cells than WT controls (Figure 9B). Taken 
together, this data shows that TFEB inhibits the WNT/β-catenin pathway in part by 
competitively binding β-catenin in the nucleus and hindering its interaction with TCF.  
Figure 9. Immunoblots for the indicated proteins after immunoprecipitations of nuclear lysates from 
(A) WT 293T cells with our with TFEB S211A, and (B) WT or TFEB KO 293T cells. 
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During the nuclear immunoprecipitations, we noted that β-catenin levels were consistently 
increased in TFEB KO cells compared to WT cells. Thus, we determined if TFEB regulates 
the stability of β-catenin. We found that in the WNT ON state, TFEB KO cells have 
significantly higher levels of β-catenin than WT controls. We also found that overexpression 
of TFEB significantly decreases β-catenin levels in the WNT ON but not the WNT OFF 
state. Using a series of sequential immunoprecipitations, we then confirmed that TFEB 
interacts with free β-catenin but not β-catenin as part of the WNT destruction complex. 
Importantly, this finding mechanistically explains why TFEB negatively regulates WNT/ β-
catenin signaling only in the WNT ON state. Finally, we determined that overexpression of β-
catenin also reciprocally decreases levels of TFEB, suggesting the TFEB/β-catenin may be 
targeted for degradation. 
In summary, we identified TFEB as a novel repressor of the WNT/β-catenin signaling 
pathway. We determined that TFEB inhibits WNT/β-catenin signaling by two mechanisms. 
First, it competitively binds β-catenin in the nucleus, inhibiting its ability to bind TCF/LEF 
and activate WNT target genes. Second, TFEB directly binds and promotes the degradation 
of free β-catenin, decreasing its overall levels. Notably, β-catenin reciprocally promotes the 
degradation of TFEB, suggesting that these two pathways reciprocally regulate one another. 
  
3.4 SARS-CORONAVIRUS OPEN READING FRAME-3A DRIVES 
MULTIMODAL NECROTIC DEATH BY INSERTING INTO MEMBRANES 
The SARS-CoV causes illness with a 10% mortality rate; it presents as flu-like symptoms but 
can rapidly progress to respiratory failure [271, 272]. Lung tissue from fatal cases exhibits 
severe inflammation, showing diffuse alveolar damage and infiltration of inflammatory 
monocyte-macrophages (IMMs) [273, 274]. It is now understood that the lung damage is not 
simply caused by the virus itself, but rather by both cytotoxic effects of the virus and an 
aberrant host inflammatory response to viral components [275]. A recent study in mouse 
models highlighted the importance of IMMs in SARS pathogenesis, as depletion of these 
cells rescues infected mice from fatal challenge [275]. Though the importance of IMMs in 
SARS pathogenesis is now appreciated, the mechanisms mediating their aberrant 
inflammatory state remain poorly understood. The SARS-CoV codes eight accessory 
proteins, of which open reading frame-3a (SARS 3a) is of interest as deletion of ORF-3a 
rescues mice from lethal challenge in murine models [276]. SARS 3a has been shown to 
oligomerize based on the formation of disulfide bonds at its Cys133 residue, enabling it to 
insert into membranes and function as a potassium ion channel [277]. In this paper, we 
investigated downstream consequences of SARS 3a membrane insertion. 
Based on structural similarities between the necroptosis effector protein MLKL and SARS 
3a, namely the ability to oligomerize and insert into membranes, we investigated whether 
RIPK3 could target SARS 3a to drive necrotic death.   
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Overexpression of SARS 3a caused very little 
necrotic death alone, but induced significant necrotic 
death as assayed by protease release and ATP 
depletion when co-expressed with RIPK3 (Figure 
10A). Notably, SARS 3a induced cell death was not 
inhibited by addition of a pan-caspase inhibitor, 
further suggesting necrotic death. Time lapse 
confocal imaging confirmed that expression of SARS 
3a in the presence of RIPK3 induces rapid cell death, 
and we next found that SARS 3a and RIPK3 interact 
when co-expressed. Next, we determined if RIPK3-
SARS 3a mediated cell death was dependent on 
SARS 3a oligomerization and RIP3K’s kinase 
activity. Co-transfection of RIP3K and the SARS 3a 
C133A oligomerization deficient mutant reduced cell 
death compared to WT SARS 3a, indicating 
oligomerization of SARS 3a plays a role in cell death. 
However, the RIP3K kinase dead mutant induced cell 
death to similar levels as WT RIP3K when expressed 
with SARS 3a, indicating RIP3K’s kinase activity is 
dispensable for SARS 3a induced necrotic death. 
Having shown that SARS 3a 
oligomerization is important for cell 
death, we checked whether RIPK3 
enhances SARS 3a oligomerization. 
Notably, both WT RIPK3 and kinase 
dead RIPK3 enhanced SARS 3a 
oligomerization, which is consistent 
with previous findings. We validated 
the oligomer band, as both reduction 
of lysates with DTT and heating of 
cross-linked samples to 100 oC 
abrogated oligomer detection (Figure 
11A). Finally, we validated that SARS 
3a similarly causes cell death in a 
human lung cell line expressing 
endogenous RIP3 (A459 treated with 
the hypomethylating agent decitabine) 
[278]. These results underscore the 
pathophysiological relevance of SARS 
3a induced necrosis. 
Figure 10. (A) ATP depletion (top) and membrane 
leakage (bottom) in cells expressing SARS-3a with 
or without RIP3. Adapted from figure first 
published in Yue et al, Cell Death Dis, 2018: 904 
Figure 11. (A) Immunoblotting showing the 
oligomerization of SARS-3a is driven by RIP3K. Adapted 
from figure first published in Yue et al, Cell Death Dis, 
2018: 904 
 36 
Next, we investigated the pathophysiological consequences of SARS 3a insertion into 
membranes other than the plasma membrane. Co-transfection of SARS 3a and RIP3K results 
in clear lysosomal co-localization, which results in lysosomal damage as assayed by galectin-
3 puncta formation [279]. Consistently, SARS 3a expressing cells showed defective 
lysosomal degradation capacity, as well as cytosolic cleavage of Bid consistent with release 
of lysosomal cathepsins into the cytosol. Unsurprisingly, TFEB nuclear localization was seen 
accompanying lysosomal damage, causing upregulation of TFEB target genes. Finally, as 
SARS 3a is known to function as a potassium channel and the NLRP3 inflammasome is 
activated by potassium efflux, we tested whether SARS 3a triggers the NLRP3 
inflammasome.  Transfection of SARS 3a into the human macrophage cell line Thp-1 results 
in significant caspase-1 cleavage, suggesting activation of pyroptotic pathways in 
inflammasome competent cells. In summary, we identified that SARS 3a induces necrotic 
cell death by direct insertion into the plasma membrane, which is promoted by RIPK3 
mediated oligomerization. We find that in inflammasome competent cells, SARS 3a drives 
IL-1β release and pyroptotic death. These mechanisms may contribute to the aberrant 
systemic inflammation seen patients following SARS-CoV infection. 
  
3.5 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
The aim of this thesis was to elucidate molecular mechanisms by which cells of the innate 
immune system transduce and integrate extracellular signals to generate a coordinate 
biological response. This thesis provides insights into multiple signaling pathways effecting 
macrophage function and uncovers crosstalk mechanisms by which cells adapt to stressful 
stimuli. Specifically, the major findings of this thesis are: 
• The identification of Gαi2 as a critical regulator of macrophage polarization, with 
sigificant effects on important processes including cytokine release, inflammasome 
priming, and T cell supression. 
• The discovery and description of a novel CD38-LRRK2-TFEB signaling pathway 
that is present in both B-cells and macrophages.   
• The identification of TFEB as a novel repressor of the WNT/β-catenin signaling 
pathway and detailed elucidation of the molecular mechanisms by which TFEB 
inhibits the WNT signaling pathway. 
• The identification that SARS ORF-3a causes necrotic cell death via RIPK3 mediated 
oligomerization and activates the NLRP3 inflammasome in immune cells, which may 
contribute to the aberrant inflammatin seen in SARS-CoV infected patients. 
Paper I identifies Gαi2 as a critical regulator of macrophage polarization, showing that excess 
Gαi2 signaling biases macrophages towards a proinflammatory M1 phenotype while defective 
Gαi2 signaling biases macrophages towards the alternatively activated M2 phenotype. There 
are several lines of investigation worth exploring in following up this study. One particularly 
interesting observation was that while Gαi2 deficient macrophages release significantly less 
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IL-1β than WT macrophages upon inflammasome activation, short-term inhibition of Gαi2 
with PTX (overnight) did not recapitulate this phenotype. This observation suggests that 
signaling downstream of TLR4 during LPS priming is not responsible for the macrophage 
polarization phenotype that manifests as decreased IL-1β release, because short-term PTX 
treatment also inhibits nucleotide exchange during LPS stimulation. It is unlikely that 
nucleotide exchange independent effects of Gαi2 are responsible for these changes, given the 
reciprocal phenotypes of Gαi2 deficient and G184S KI BMDMs. We observed that long term 
inhibition of Gαi2 with PTX (7 days) during development was able to recapitulate the 
macrophage polarization phenotype seen in Gαi2 deficient macrophages. The important 
question that remains unanswered is whether prolonged Gαi2 inhibition itself can reprogram 
macrophages towards the M2 phenotype, or whether Gαi2 inhibition during differentiation is 
critical to mediating reprogramming. The former scenario has major therapeutic implications, 
as long-term targeting of macrophage specific Gαi2-coupled GPCRs could lay the foundation 
for the treatment of several diseases via macrophage reprogramming [266].  
Paper II identifies a novel CD38-LRRK2-TFEB signaling pathway in B cells and 
macrophages. This is the first paper to identify LRRK2 as part of the signaling cascade 
downstream of CD38, as the mechanisms mediating CD38 signaling are largely unknown. 
The work in this paper has several clinical implications, as monoclonal antibodies against 
CD38 are already FDA approved for multiple myeloma and LRRK2 inhibitors are currently 
in clinical trials for the treatment of PD. With regards to the implications of this study for the 
development of cancer therapeutics, it has already been reported that Daratumumab induces 
apoptosis following cross-linking in a variety of hematologic cell lines. Our study shows that 
inhibition of LRRK2 during Daratumumab cross-linking enhances cell death in the Ramos 
Burkitt’s lymphoma cell line, warranting follow up on the role of LRRK2 inhibitors as 
adjuvant therapy for Daratumumab. The monoclonal antibody Isatuximab currently in phase 
III clinical trials has been shown to initiate lysosomal cell death characterized by cytoplasmic 
cathepsins. As we also show that CD38 controls the activation of TFEB, it will be interesting 
to see if TFEB has any role in the observed lysosomal cell death following Isatuximab 
treatment. With regards to LRRK2 inhibitors in clinical trials, this study underscores that 
LRRK2 has significant immune function. Clinicians administering LRRK2 inhibitors must 
remain vigilant to the fact that LRRK2 inhibitors could increase patient risk for serious 
infections by inhibiting LRRK2’s immune function. 
Paper III identifies TFEB is a negative regulator of the WNT/β-catenin signaling pathway 
and elucidates some of the molecular mechanisms mediating TFEB repression of WNT. We 
find that TFEB directly binds β-catenin in the nucleus, and that this interaction may hinder β-
catenin/TCF binding required for the activation of WNT target genes. We also find that 
TFEB promotes the degradation of β-catenin, potentially through direct binding of free β-
catenin and subsequent degradation of the complex. It remains unclear what role, if any, 
TFEB transcriptional targets have in TFEB mediated inhibition of WNT signaling. It may be 
illuminating to perform these studies with TFEB constructs that are unable to activate 
transcription. Furthermore, it may be useful to extend the scope of these studies to 
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physiological contexts. The drawback of this study is that WNT signaling was activated by 
transfection of WNT3A, which results in very high levels of expression. Similar studies using 
recombinant WNT ligands may be more relevant to the physiological context. Furthermore, 
TFEB overexpression was frequently used in this study to activate TFEB. It may be useful to 
determine if TFEB still strongly affects WNT signaling when activated by physiological 
inducers of TFEB activity, such as starvation or initiation of cell stress pathways.  
Paper IV implicates the SARS-CoV ORF-3a protein in necrotic cell death. SARS 3a 
mediated necrotic death occurs after SARS 3a oligomerization and membrane insertion, 
which is enhanced by RIPK3. We also show that oligomerized SARS 3a can insert into 
lysosomal membranes, causing lysosomal damage and triggering cell stress. Lastly, we show 
that SARS 3a can activate the NLRP3 inflammasome, potentially activating pyroptotic death 
in inflammasome competent cells. While it is already known that deletion of SARS 3a 
rescues murine models from lethal challenge, it would be interesting to determine if 
abrogation of SARS 3a oligomerization by genetic mutation similarly rescues mice from 
lethal challenge. If oligomerization of SARS 3a is in fact a key mechanism for promoting 
aberrant inflammation, targeted therapies blocking this can be developed. Furthermore, the 
IMMs that have been implicated as important in SARS pathogenesis presumably express 
both high levels of RIP3K and of NLRP3. Blocking these two pathways that initiate the 
inflammatory cascade may help prevent the aberrant inflammatory response associated with 
SARS-CoV infection.  
In conclusion, this work expands our knowledge of the cell signaling pathways important in 
innate immunity. The results underscore the complexity of cell signaling networks, and open 
up new avenues worthy of future study.  
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